Navamedic — Share Issue/Capital Change 2021

Jan 4, 2021

Navamedic ASA – Resolution to issue consideration shares in connection with the acquisition of marketing authorisations for antibiotics in the Nordics

Navamedic ASA – Resolution to issue consideration shares in connection with the acquisition of marketing authorisations for antibiotics in the Nordics

Oslo, 4 January 2021: Reference is made to Navamedic ASA's ("Navamedic" or the "Company") stock exchange announcement published on 4 August 2020 regarding the completion of the transaction with ACS Dobfar and InfoRLife for the acquisition of marketing authorisations for a series of antibiotics for hospital use in the Nordic region (the "Transaction").

The board of directors of Navamedic has today, on 4 January 2021, pursuant to the authorisation granted to it by the extraordinary general meeting held on 11 March 2020, resolved to settle the first tranche of the purchase price in the Transaction for an amount of NOK 19 million by issuance of 1,053,775 new shares to InfoRLife. The resolution to issue the 1,053,775 new shares entails an increase of the Company's share capital of NOK 779,793.50.

The subscription price for the new shares is NOK 18.0304 per share, which corresponds to the volume weighted average trading price of the Navamedic shares from 24 January to 6 February 2020, being the 10 last trading days prior to, but not including, Navamedic's stock exchange announcement published on 7 February 2020.

Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the Company's new share capital is 12,095,788.40, divided into 16,345,660 shares, each with a par value of NOK 0.74.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to the issuer rules for Oslo Børs.